Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 37, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s13046-018-0707-5
Keywords
NSCLC; ALK-targeted therapy; Alectinib; Crizotinib; HGF-MET signaling; Therapeutic resistance; Autophagy; LIR motif; Combined treatment
Categories
Funding
- National Natural Science Foundation of China [81502975]
- China Postdoctoral Science Foundation [2016 T90413, 2015 M581693]
- Jiangsu Planned Projects for Postdoctoral Research Funds [1501002A]
- Fundamental Research Funds for the Central Universities [2242016R20027, 2242016 K41045]
Ask authors/readers for more resources
Non-small-cell lung cancer (NSCLC) is currently the leading cause of cancer-related death. Accumulating evidences suggest that overcoming the therapeutic resistance in NSCLC is a big challenge. Recently, the outcomes of two independent phase 3 trials regarding Alectinib versus Crizotinib in ALK-positive NSCLC are encouraging. However, given the potential relevance of HGF-MET signaling and especially autophagy to the war against ALK-positive NSCLC between Alectinib and Crizotinib, it's too early to reach a convincing conclusion. Therefore, to further improve the therapeutic efficacy of ALK-positive NSCLC, this commentary highlights the negligence in design of relevant clinical trials, emphasizes the importance of molecular characteristics investigation, and discusses the prospect of combination therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available